Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,557 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
Piehl F, Alping P, Virtanen S, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Mellergård J, Nilsson P, Olsson T, Salzer J, Svenningsson A, Frisell T. Piehl F, et al. Among authors: nilsson p. Ann Neurol. 2024 Oct;96(4):678-693. doi: 10.1002/ana.27012. Epub 2024 Jun 25. Ann Neurol. 2024. PMID: 38923558
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Luna G, et al. Among authors: nilsson p. JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365. JAMA Neurol. 2020. PMID: 31589278 Free PMC article.
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Alping P, et al. Among authors: nilsson p. Ann Neurol. 2020 May;87(5):688-699. doi: 10.1002/ana.25701. Epub 2020 Mar 9. Ann Neurol. 2020. PMID: 32056253 Free article.
COVID-19 clinical outcomes and DMT of MS patients and population-based controls.
Longinetti E, Bower H, McKay KA, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Piehl F, Frisell T. Longinetti E, et al. Among authors: nilsson p. Ann Clin Transl Neurol. 2022 Sep;9(9):1449-1458. doi: 10.1002/acn3.51646. Epub 2022 Aug 22. Ann Clin Transl Neurol. 2022. PMID: 35993445 Free PMC article.
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
Longinetti E, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould AM, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Piehl F, Frisell T. Longinetti E, et al. Among authors: nilsson p. J Neurol Neurosurg Psychiatry. 2024 Jan 11;95(2):134-141. doi: 10.1136/jnnp-2023-331784. J Neurol Neurosurg Psychiatry. 2024. PMID: 37558400 Free PMC article.
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort.
Englund S, Kierkegaard M, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Longinetti E, Frisell T, Piehl F. Englund S, et al. Among authors: nilsson p. Mult Scler Relat Disord. 2023 Feb;70:104481. doi: 10.1016/j.msard.2022.104481. Epub 2022 Dec 23. Mult Scler Relat Disord. 2023. PMID: 36603296 Free article.
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hägglund H, Carlson K, Fagius J. Burman J, et al. Among authors: nilsson p. J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1116-21. doi: 10.1136/jnnp-2013-307207. Epub 2014 Feb 19. J Neurol Neurosurg Psychiatry. 2014. PMID: 24554104
Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
Tedeholm H, Piehl F, Lycke J, Link J, Stawiarz L, Burman J, de Flon P, Fink K, Gunnarsson M, Mellergård J, Nilsson P, Sundström P, Svenningsson A, Johansson H, Andersen O. Tedeholm H, et al. Among authors: nilsson p. Mult Scler Relat Disord. 2022 Dec;68:104220. doi: 10.1016/j.msard.2022.104220. Epub 2022 Oct 5. Mult Scler Relat Disord. 2022. PMID: 36242804 Free article.
2,557 results